No specific pharmacological information is provided

This product is an oral third-generation cephalosporin with a broad antibacterial spectrum. It has antibacterial activity against some Gram-positive and Gram-negative bacteria, especially against Streptococcus (except Enterococcus) and Pneumococcus among Gram-positive bacteria, and gonococci, Branhamella, Escherichia coli, Klebsiella, Serratia, Proteus, and influenza bacilli among Gram-negative bacteria. Its mechanism of action is to prevent the synthesis of bacterial cell walls. Its action point varies with the type of bacteria. It has a high affinity with PBP1 (la, lb, lc) and PBP3 among penicillin-binding proteins (PBP). This product has strong stability against β-lactamases produced by various bacteria.

1. It is a non-selective competitive inhibitor of adrenergic β-receptor blocker, blocking β1 and β2 receptors on the heart, antagonizing sympathetic nerve excitation and catecholamine effects, reducing the contractile force and contractile speed of the heart, while inhibiting vascular smooth muscle contraction, reducing myocardial oxygen consumption, and restoring the oxygen supply and demand relationship of ischemic myocardium to a low level of balance, which can be used to treat angina pectoris. 2. It inhibits the adrenergic excitement of cardiac pacemaker potentials and is used to treat arrhythmias. 3. It can be used to treat hypertension by blocking central and adrenergic neurons, inhibiting renin release and reducing cardiac output. 4. It competitively antagonizes the effects of isoproterenol and norepinephrine, blocks β2 receptors, and reduces plasma-related activity.

Not yet clear